A practical reference on Preclinical study: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-13. Anything still debated is marked as such rather than presented as settled.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Assessing the Cardinals' pennant chances during 1957 spring training, manager Fred Hutchinson said, "We've got at least three pitchers capable of winning 20-Herm Wehmeier, Sam Jones, and Vinegar Bend Mizell. If a couple of them can do it, we'll make plenty of trouble." Mizell's fastball had slowed a bit in 1956, and it was even slower in 1957. He was giving up more home runs than he had before he joined the Army, and the Cardinals were worried about his weight and his windup motion. Mizell spent much of the early part of the season in the bullpen, and the Cardinals even attempted to send him to Houston, but they were unable to get him through waivers. They had him watch films of his pitching, not common practice at the time, to help him correct his mistakes. On July 18, he relieved Hoyt Wilhelm in the ninth inning with the Cardinals leading the Dodgers 9–4 and the bases loaded. He retired Duke Snider on a groundout but then walked Gino Cimoli to bring up Gil Hodges, a right-handed hitter. Though many managers would have inserted a right-hander in this situation, Hutchinson left Mizell in to face him, and Hodges hit a grand slam, tying the game, which the Cardinals eventually lost 10–9. The decision drew ire from St. Louis fans, and general manager Frank Lane and executive vice president Richard A.
sex linkage The presence of a particular gene or DNA sequence on a sex chromosome (in mammals either the X chromosome or the Y chromosome) rather than on an autosome; these genes are said to be sex-linked. Expression of sex-linked genes varies by organism depending on the mechanism of sex determination and the types of sex chromosomes present, but the associated phenotypes often exclusively appear in either the homogametic or heterogametic sex.
In 1952, L. V. Radushkevich and V. M. Lukyanovich published clear images of 50-nanometre diameter tubes made of carbon in the Journal of Physical Chemistry of Russia. This discovery was largely unnoticed, as the article was published in Russian, and Western scientists' access to Soviet press was limited during the Cold War. Monthioux and Kuznetsov mentioned in their Carbon editorial: The fact is, Radushkevich and Lukyanovich [...] should be credited for the discovery that carbon filaments could be hollow and have a nanometre-size diameter, that is to say for the discovery of carbon nanotubes. In 1976, Morinobu Endo of CNRS observed hollow tubes of rolled up graphite sheets synthesised by a chemical vapour-growth technique. The first specimens observed would later come to be known as single-walled carbon nanotubes (SWNTs). Endo, in his early review of vapor-phase-grown carbon fibers (VPCF), also reminded us that he had observed a hollow tube, linearly extended with parallel carbon layer faces near the fiber core. This appears to be the observation of multi-walled carbon nanotubes at the center of the fiber. Mass-produced MWCNTs are strongly related to the VPGCF developed by Endo. In fact, they call it the "Endo process", out of respect for his early work and patents. In 1979, John Abrahamson presented evidence of carbon nanotubes at the 14th Biennial Conference of Carbon at Pennsylvania State University. The conference paper described carbon nanotubes as carbon fibers that were produced on carbon anodes during arc discharge.
Sources: en.wikipedia.org
This was also the belief of geologist Palmer, who convinced Steven Jones that the helium-3 occurring naturally in Earth perhaps came from fusion involving hydrogen isotopes inside catalysts like nickel and palladium. This led their team in 1986 to independently make the same experimental setup as Fleischmann and Pons (a palladium cathode submerged in heavy water, absorbing deuterium via electrolysis). Fleischmann and Pons had much the same belief, but they calculated the pressure to be of 1027 atmospheres, when cold fusion experiments achieve a loading ratio of only one to one, which has only between 10,000 and 20,000 atmospheres. John R. Huizenga says they had misinterpreted the Nernst equation, leading them to believe that there was enough pressure to bring deuterons so close to each other that there would be spontaneous fusions.
== Pets == Wheatgrass is also cultivated for feeding to pet cats. Wheatgrass, along with shoots of other common grains such as oats, rye and barley, is sold for this purpose, including under the name cat grass. Many cats enjoy eating grass and wheatgrass is considered safe and healthy for them. It may provide nutrients and improve digestion by adding fiber to the diet. Eating wheatgrass may also provide mental stimulation. However, it is recommended to limit the quantity allowed, to avoid indigestion.
In a prebiotic context, they argued that seawater would likely still be buffered and ferrous iron could inhibit oxidation. Steam and hydrogen sulfide. In 1999, after Miller suffered a stroke, he donated the contents of his laboratory to Bada. In an old cardboard box, Bada discovered unanalyzed samples from modified experiments that Miller had conducted in the 1950s. In a "volcanic" apparatus, Miller had amended an aspirating nozzle to shoot a jet of steam into the reaction chamber. Using high-performance liquid chromatography and mass spectrometry, Bada's lab analyzed old samples from a set of experiments Miller conducted with this apparatus and found some higher yields and a more diverse suite of amino acids. Bada speculated that injecting the steam into the spark could have split water into H and OH radicals, leading to more hydroxylated amino acids during Strecker synthesis. In a separate set of experiments, Miller added hydrogen sulfide (H2S) to the reducing atmosphere, and Bada's analyses of the products suggested order-of-magnitude higher yields, including some amino acids with sulfur moieties. Free electrons and charged microdroplets. A 2021 work highlighted the importance of the high-energy free electrons present in the experiment. It is these electrons that produce ions and radicals, and represent an aspect of the experiment that needs to be better understood. A 2025 study used charges from sprays of water instead of lightning to produce electricity.
=== External relationships === The teleosts were first recognised as a distinct group by the German ichthyologist Johannes Peter Müller in 1845. The name is from Greek teleios, "complete" + osteon, "bone". Müller based this classification on certain soft tissue characteristics, which would prove to be problematic, as it did not take into account the distinguishing features of fossil teleosts. In 1966, Greenwood et al. provided a more solid classification. The oldest fossils of teleosteomorphs (the stem group from which teleosts later evolved) date back to the Triassic period (Prohalecites, Pholidophorus). However, it has been suggested that teleosts probably first evolved already during the Paleozoic era. During the Mesozoic and Cenozoic eras they diversified widely, and as a result, 96% of all living fish species are teleosts. The cladogram below shows the evolutionary relationships of the teleosts to other extant clades of bony fish, and to the four-limbed vertebrates (tetrapods) that evolved from a related group of bony fish during the Devonian period. Approximate divergence dates (in millions of years, mya) are from Near et al., 2012.
Sources: en.wikipedia.org
As of 2025, Einstein has over 2,000 faculty members, yielding a faculty-student ratio of 2.6:1. Faculty members that have taught or are currently teaching at Einstein include 18 members of the National Academy of Sciences and five members of the American Academy of Arts and Sciences. One faculty member—William R. Jacobs Jr.—has been a Howard Hughes Medical Investigator. Neurologist and writer Oliver Sacks taught at the college for over 40 years. His 1973 book Awakenings—documenting his work with encephalitis lethargica in the Bronx—was adapted into a 1990 film starring Robin Williams and Robert De Niro. In 1983, professor Berta Scharrer, considered the co-founder of neuroendocrinology, was awarded the National Medal of Science for establishing the concept of neurosecretion. In 1987, professor Harry Eagle was awarded the National Medal of Science for developing Eagle's minimal essential medium (MEM), widely used for cell culture. Genetics professor Salome Gluecksohn-Waelsch was a Royal Society Fellow and received the National Medal of Science in 1993 for her fundamental research on mammalian genetics. Professor Michael Baden served as Chief Medical Examiner of New York City.
== Use and effects == EiPLA has been identified in blotter containing doses of 86 to 97 μg base equivalent per tab. Blotter containing 200 μg per tab has also been described. Anecdotal reports suggest that EiPLA produces psychedelic effects but is less potent than LSD.
Following that investigation and one of their own that faulted the university for failing to act on warnings and protect the campus, the university's faculty senate voted "no confidence" in the president and many other leaders at the university. In 2023, the University of Arizona faced a financial crisis, allegedly "losing track of more than $240 million through accounting errors and flawed financial projections." Subsequent investigative reporting by The Arizona Republic linked much of the crisis to the university's purchase of Ashford University, accusing university administrators of knowing that Ashford was experiencing "a downward enrollment spiral that began years before [the purchase] and dismal graduation and retention rates". In April 2024, the UA chapter of Students for Justice in Palestine joined student protests across the USA against the war in Gaza, during what they called "Israeli Apartheid Week". The encampment was attacked and dispersed by police firing rubber bullets, tear gas and pepper balls. Bystanders and press were also hurt in the police violence. The students were protesting against UA involvement with companies supporting the "genocide and ethnic cleansing in Palestine" and called for divestment.
Romergoline (INNTooltip International Nonproprietary Name; developmental code name FCE-23884) is a dopamine receptor modulator of the ergoline family which was under development for the treatment of Parkinson's disease and psychotic disorders but was never marketed. It is closely related to the psychedelic drug LSD in terms of chemical structure, though it is not technically a lysergamide itself as the oxygen atom of LSD's carboxamide moiety has been removed to instead form an aminomethyl moiety.
Lori stated that he would be taking a sabbatical from the program until he recovers. She blamed the stroke on Bakker's hard work on his show and wrote that he had described the criticism against him as "the most vicious attack that he has ever experienced". Bakker returned to his program for the first time following his stroke on July 8, 2020. On June 23, 2021, Missouri Attorney General Eric Schmitt announced the settlement of the state's lawsuit against Bakker. Bakker and Morningside Church would be prohibited from saying silver solution could "diagnose, prevent, mitigate, treat, or cure any disease or illness". Restitution of about $157,000 would also be paid to those who bought silver solution between February 12, 2020, and March 10, 2020.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.